Characterization and anti - Microbial susceptibility of gram - Negative bacteria isolated from bloodstream infections of cancer patients on chemotherapy in Pakistan

Indian Journal of Medical Microbiology

Volumn 27, Issue 4, 2009, Pages 341-347

  Saghir, S ^a   Faiz, M ^b   Saleem, M ^a   Younus, A ^a   Aziz, H ^b  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b Institute of Nuclear Medicine and Oncology (INMOL)   (Pakistan)

Author keywords

Bloodstream infection; Cancer patients; Enterobacteriaceae; Gram negative bacteria; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFOPERAZONE; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; IMIPENEM; MEROPENEM; QUINOLONE DERIVATIVE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLI; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BLOOD CULTURE; BLOODSTREAM INFECTION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CROSS RESISTANCE; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HUMAN; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PAKISTAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS;

EID: 70349334319     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/0255-0857.55454     Document Type: Article

References (24)

1. Hugonnet S, Sax H, Eggimann P, Chevrolet CJ, Pittet D. Nosocomial bloodstream infection and clinical sepsis. Emerg Infect Dis 2004;10:76-81.
2. Oudhuis GJ, Verbon A, Hoogkamp-Korstanje JA, Stobberingh EE; Susceptibility Surveillance Study Group. Susceptibility Surveillance Study Group. Antimicrobial resistance in Escherichia coli and Pseudomonas aeruginosa from Intensive Care Units in The Netherlands, 1998-2005. Int J Antimicrob Agents 2008;31:58-63.
3. Paul M, Gafter-Gvili A, Leibovici L, Bishara J, Levy I, Yaniv I, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Isr Med Assoc J 2007;9:424-429
4. Cheesbrough M. District Laboratory Practice in Tropical Countries. 1st ed. Cambridge University Press; 2005.
5. NCCLS. Performance standard for antimicrobial susceptibility testing. Twelfth Information Supplement. NCCLS. 2000; Document. M100- S12 (ISBN, 1- 56238-456-4) NCCLS, 940 West Valley Road, Suite, 1400, Wayne, PA: 19087-21898 USA.
6. Stürenburg E, Mack D. Extended. spectrum Beta lactamases: Implications for clinical microbiology laboratory, therapy, and infection control. J Infect 2003;47:273-295
7. Livermore DM, Brown DF. Detection of beta lactamase- mediated resistance. J Antimicrob Chemother 2001;48:59-64.
8. Gangoue-Pieboji J, Koulla-Shiro S, Ngassam P, Adiogo D, Ndumbe P. Antimicrobial activity against Gram-negative bacilli from Yaounde Central Hospital, Cameroon. Afr Health Sci 2006;6:232-235
9. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE. And Calandria T, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clini Infest Dis 2002;34:730-751
10. Prakash S. Carbapenem sensitivity profile amongst bacterial isolates from clinical specimens in Kanpur city. Indian journal of Critical Care Medicine 2006;10:250-253
11. O.Neill E, Humphreys H, Phillips J, Smyth EG. Third- generation cephalosporin resistance among Gram-negative bacilli causing meningitis in neurosurgical patients: significant challenges in ensuring effective antibiotic therapy. J Antimicrob Chemother 2006;57:356-359
12. Wenzel PR, Sahm FD, Thornsberry C, Draghi DC, Jones EM, Karlowsky JA. In vitro Susceptibilities of Gram- Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000- 2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy. Antimicrob Agents Chemother 2003;47:3089-3098
13. Spanu T, Luzzaro FM, Perilli M, Amicosante GA, Toniolo A, Fadda G; The ESBL Italian study group. Occurrence of Extended-Spectrum ß-Lactamases in Members of the Family Enterobacteriaceae in Italy: Implications for Resistance to ß-Lactams and Other Antimicrobial Drugs. Antimicrobial Agents Chemother 2002;46:196-202.
14. Pfaller MA, Jones RN. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections. J Antimicrob Chemother 2000;46:25-37.
15. Goossens H. For the MYSTIC Study Group (European Centres). MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: Comparison of antibiotic susceptibilities between countries and centre types. J Antimicrob Chemother 2000;46:39-52.
16. Kern VW, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, Von Baum H, Marre R. Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophylactic ß uoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005;24:111-118
17. Reynolds R, Potz N, Colman M, Willaims A, Livermore D, Macgowan A. Antimicrobial susceptibility of the pathogens bacteremia in the UK and Ireland between 2001- 2002: The BSAC bacteremia in the UK and Ireland between 2001- 2002: BSAC Bacteremia resistance surveillance programme. J Antimicrob Chemother 2004;53:1018-1032
18. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland JR, Sahm DF. Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-1688
19. Gencer S, Ak O, Benzonana N, Batirel A, Ozer S. Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey. Ann Clin Microbiol Antimicrob 2002;1:2. vol mentioned now
20. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997.2002). Diagn Microbiol Infect Dis 2004;50:59-69.
21. Raja NS, Singh NN. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital. J Microbiol Immunol Infect 2007;40:45-49
22. Spanu T, Luzzaro FM, Perilli M, Amicosante GA, Toniolo A, Fadda G. Occurrence of Extended-Spectrum ß-Lactamases in Members of the Family Enterobacteriaceae in Italy: Implications for Resistance to ß-Lactams and Other Antimicrobial Drugs Antimicrobial Agents Chemotherapy 2001;46:196-202.
23. Paterson DL, Ko CW, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended- spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-2212
24. Shivaprakasha S, Radhakrishnan KA, Gireesh KP. Routine Screening for ESBL Production, a Necessity of Today. The Internet Journal of Microbiology 2007;3:1-8.